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ABSTRACT 
Generation of Human Immunodeficiency Virus Type-1 Escape Mutants to Peptide 
Triazole Entry-Inhibiting Virus Inactivators 
Andrew Patrick Holmes 
Irwin Chaiken, Ph.D. 
 
 
 
A study was performed to evolve resistant HIV-1 variants to multiple classes of peptide 
triazole entry inhibitors in order to understand the mechanisms of virus escape and 
inactivation.  The macrocyclic and sulfhydryl-containing peptides used in this study are 
both capable of inactivating the virus through gp120 shedding, but the latter class has the 
additional ability to induce cell-free virolysis.  Generation of HIV-1 escape mutants was 
accomplished through virus passaging on an immortalized T-cell line with dose escalation 
of inhibitor.  Over the course of approximately four months, resistant virus cultures were 
established that grow under peptide concentrations that are two orders of magnitude greater 
than the starting concentration.  Traditional Sanger sequencing of the escape mutant HIV-
1 genome revealed similar escape profiles for both classes despite the difference between 
their inactivating effects.  Mutations within the putative binding site and around the HIV-
1 Env protein were discovered, including at the gp120-gp41 interface and the trimer apex, 
supporting the hypothesis that peptide triazoles actuate inactivating pressure throughout 
the protein complex.  From this pool of mutations, individual and combinational mutations 
were generated in an envelope pseudotyped virus system by site-directed mutagenesis to 
investigate the mechanism of escape.  Small changes in the side chain at a pivotal location 
	 xi	
between the peptide binding cavities on gp120, V255I/T, were found to have a profound 
effect on inhibitor function.  Flexible molecular docking of peptide triazoles onto HIV-1 
Env trimers in the presence and absence of the V255 mutations suggests that the mutation 
fills an important binding cavity and prevents inhibitor penetration into the protein.  The 
results of this work demonstrate that a major pathway of HIV-1 escape from peptide 
triazole virus inactivators occurs through binding site disruption, with other escape 
potentially observed by alterations in Env gp120 shedding and infectivity.	
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Chapter 1:  Introduction 
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1.1.  The AIDS Epidemic 
 
The human immunodeficiency virus type 1 (HIV-1), the causative agent for acquired 
immunodeficiency syndrome (AIDS), remains a global health problem despite being 
discovered more than 30 years ago [1].  Over the past 30 years, the perception, treatment 
and life expectancy of infected individuals have changed dramatically. The disease has 
gone from being a death sentence to a highly controllable illness with access to proper 
treatments.  These significant changes are made possible with huge efforts from the 
research community and the extensive medical outreach programs around the world. 
 
The infection that we now know as HIV-1 was originally found through an observation of 
infections of pneumocystis, a yeast-like fungus that is rarely observed in healthy patients, 
within the gay population of San Francisco [2].  Some underlying factor was believed to be 
occurring within these individuals that opened them up to opportunistic infections.  This 
led the field to hypothesize about the cause of this immunodeficiency.  Eventually, a few 
groups began isolating retroviruses with the ability to kill immune cells and to develop the 
immunodeficiency phenotype observed in patients [3-5].  These viruses were later shown to 
be the same agent and given the name of human immunodeficiency virus by the 
International Committee on Taxonomy of Viruses [6]. 
 
The discovery of the causative agent of AIDS allowed the scientific community to begin 
investigating therapeutic approaches to combat the viral infection.  Therapeutics were 
quickly discovered to target HIV-1 based on available drugs used to treat cancer and other 
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viral infections such as Herpes Simplex Virus [7, 8].  These drugs targeted the viral reverse 
transcriptase enzyme, mimicked the natural nucleoside ligands, and caused chain 
termination of the newly synthesized strand of DNA [9].  Collectively, these drugs are 
known as nucleoside reverse transcriptase inhibitors (NRTIs) and rapidly became an early 
staple in HIV-1 treatment [10].   
 
The growing knowledge of the virus architecture and life cycle led to further advancement 
of the therapeutic drug repertoire.  Drugs targeting other virus proteins such as protease 
and, eventually, integrase became principal components for most treatment regimens [10-
12]. 
 
Despite all of the drug treatments, there are approximately 2 million AIDS-related deaths 
each year, globally, and roughly the same amount of newly acquired infections, with a 
majority coming from low- and middle-income countries [1, 13].  These facts confirm HIV-
1 as a continuing global health concern to the present day. 
 
1.2.  Highly Active Antiretroviral Therapy 
 
The current treatment for HIV-1 was introduced in 1996 and involves the use of highly-
active antiretroviral therapy, known as HAART.  The HAART regimen is a cocktail of 
multiple drugs, chosen from over 30 FDA-approved inhibitors, that are administered 
together to limit the risk of resistance to monotherapy [14].  Each of these drugs can be 
placed into one of six therapeutic classes targeting different stages of the virus lifecycle: 
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nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase 
inhibitors (NNRTIs), protease inhibitors (PIs), integrase inhibitors (IIs), fusion inhibitors 
(FIs), and chemokine receptor antagonists (CRAs) [14].  Each patient is screened prior to 
adoption of his or her treatment regimen to account for allergies and drug resistance.  The 
final regimen comprises of two or more inhibitors, targeting multiple drug targets, which 
limits the propensity of individual resistance to affect other drugs within the cocktail.  
Frequently, the therapy consists of a protease inhibitor and at least one type of reverse 
transcriptase inhibitor [15]. 
 
The adverse effects associated with these drugs typically lead to a drop in patient 
compliance, which ultimately facilitates drug resistance [13].  When patients relapse and 
redevelop immunodeficiency, they are administered HAART again with a different 
combination of inhibitors in order to decrease the potential for resistance.  Current data 
suggest that, if the first-line regimens fail, the second-line inhibitors are usually effective 
if they are implemented rapidly [13].  However, when all of the typical regimens are 
exhausted, patients must be put on a salvage therapy of approved HIV-1 entry and fusion 
inhibitors.  These drugs are reserved as salvage therapy because they are harder to manage, 
such as requiring regular injections and cold storage conditions, therefore making them 
impractical for standard treatment [16]. 
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1.3.  Resistance to Current Therapy 
 
Based on World Health Organization surveys collected in recent years, approximately 10 
– 17 % of treatment-naïve individuals are infected with viruses that are resistant to at least 
one antiretroviral drug [13].  This observation becomes more obvious as the number of 
surveys increases and our understanding of resistance deepens.  There are currently over 
50 different countries that participate in WHO drug resistance monitoring to investigate 
the global impact of drug resistance [13].  The observed resistance in the patient population 
can be broken down into two respective divisions:  transmitted resistance or acquired 
resistance.  
 
Transmitted resistance, as the name suggests, is the passing of a resistant virus from one 
individual into another, which generates progeny that are inherently resistant to a particular 
inhibitor or a set of inhibitors [13, 17].  Fortunately, recent data suggest that the level of 
transmitted resistance is lower than predicted [13]. An explanation for this observation is 
that the rapid scale-up of antiretroviral therapy and the proper screening of patients prior 
to initiating treatment regimens, which has hampered the transmission [13, 17].  Alternatively, 
the fitness of the resistant virus is lower, which results in the virus being transmitted at a 
lower frequency [18]. 
 
Acquired resistance, the other type of observed resistance, is the more common means of 
resistance within the population [13].  Typically, acquired resistance occurs when patients 
do not take their medication properly, resulting in suboptimal levels of HIV-1 drugs in the 
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body, which allows the virus to escape inhibition and propagate the resistant phenotype 
that has been acquired by mutation in the patient. 
 
Regardless of the mode of resistance, HIV-1 drug resistance is on the rise throughout the 
world, resulting in moderate levels of resistance, which is set at 5 to 15% of the tested 
population, roughly doubling in a five-year span [13].  In a recent WHO report, 32% of all 
of the reported surveys displayed a moderate level of resistance to some type of HIV-1 
drug class used in therapy [13].  Therefore, there is a profound need for novel HIV-1 
inhibitors that function differently from current therapeutics.  Understanding the virus 
structure and how it functions can provide the basis to develop novel intervention 
approaches. 
 
1.4.  The HIV-1 Structure and Entry Process 
 
1.4.1. HIV-1 Virion Architecture 
 
HIV-1 is a retrovirus of the lentivirus genus that is approximately 120 nm in diameter.  The 
virion is spherically shaped and encapsulated by a lipid bilayer that the virus collects from 
the host cell upon budding [19, 20].  Multiple viral proteins and two copies of viral RNA are 
packaged inside the virion.  The viral reverse-transcriptase (RT), protease (PR), and 
integrase (IN) enzymes are made as a polyprotein, Pol, which is cleaved by the viral 
protease and incorporated into the virus [19, 20].  The matrix (MA), capsid (CA), 
nucleocapsid (NC), and p7 proteins make up the viral structural proteins, which are also 
	 7	
synthesized as a polyprotein and cleaved by the viral protease to generate a mature virion 
[19].  The HIV-1 envelope (Env) protein complex is present on the outside of the virus and 
is the only exposed viral entity.  Other viral accessory proteins, such as vif, vpr, and nef, 
are packaged to aid with “hijacking” components of the infected cell and to promote the 
virus lifecycle [19].  Figure 1 illustrates the architecture of a mature HIV virion. 
 
 
 
 
 
 
 
 
Figure 1.  Schematic representation of the HIV-1 virion.  Cartoon depiction of the mature 
virion architecture of HIV-1 that highlights the viral proteins that are packaged and the 
conical shape of the viral capsid. 
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1.4.2. The Envelope Glycoprotein  
 
The HIV-1 envelope glycoprotein (Env) trimer exists as a triad of heterodimers.  Each 
protomer of the trimer consists of a transmembrane protein component, gp41, non-
covalently bound to a heavily glycosylated surface protein, gp120.  The glycosylation acts 
as a shield for the protein and can make up almost half of the weight of the protein [21-23].  
The synthesis of the glycoprotein occurs as a polyprotein, which is cleaved by furin-like 
proteases prior to export to the cell surface [24].  The cleavage allows the virus to exist in a 
high energy metastable state that is prepared for protein transitions [25].  Despite variations 
with glycosylation patterns, the gp120 surface protein is highly conserved structurally with 
all of the clades sharing similar machinery.  Comparison of sequences between the clades 
has led to the identification of 5 constant regions, termed C1-C5, and 5 variable regions, 
known as V1-V5 [23, 26].  As the name suggests, the variable loops can be highly inconsistent 
in terms of sequence, which is another feature the virus exploits to evade the host immune 
response.  Four of the five variable loops are held together by highly-conserved disulfide 
bonds that anchor the loops to the “core” gp120 protein [21].  All of these structural features 
allow the protein to shift in response to specific ligand interactions in a highly cooperative 
way.  However, the plasticity of the protein enables it to accommodate alternative ligand 
binding and still remain functional.   
 
The glycosylation and flexibility of gp120 has made it extremely difficult to determine 
structures, which in turn hampers the design of inhibitors and antibodies that can 
effectively neutralize the virus.  Early efforts of crystallization were possible by working 
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with core gp120 and CD4 [21].  The resolved structure greatly influenced our understanding 
of the protein.  Eventually other ligands were used to display the various configurations 
that the protein can adopt [27, 28].  The knowledge gained from these structures provided 
groundwork for basis of a multiple layer model of the architecture of the inner domain of 
gp120 [29, 30].  In this model, different inner domain layers of gp120 interact and shuffle 
upon CD4 binding, which enables the transitions necessary for the entry of the virus into 
the host cell (Figure 2).  
 
 
 
 
 
Figure 2. Schematic of gp120 layer shuffling upon CD4 binding.  A)  Crystal structure of 
gp120 complexed with two-domain soluble CD4 (pink, 3JWD), highlighting the different 
layer architecture and the gp41-interacting domain.  B)  Cartoon of unliganded gp120 
interacting with gp41 (left) and the inner domain rearrangement associated with CD4 
binding (right).  Inner domain layers (numbered), outer domain, (yellow), gp41 (orange), 
beta-sandwich (red), and the b20-b21 loop (blue).  Adapted from Finzi et al. 2010.  
Copyright permission granted. 
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Unliganded structures of core gp120 were also obtained that demonstrated the “core” 
gp120 preferentially adopted a CD4-bound conformation [31].  However, a highly resolved 
structure of the entire envelope complex was hard to obtain.  Cryo-electron microscopy 
and tomography were utilized and fit with gp120 crystal data to generate structures that 
can be below 10 angstrom resolution [32, 33].  A few groups have been able to determine 
high resolution structures of the Envelope complex [25, 34, 35].  This was made possible by 
either using disulfide mutations to hold the proteins together or using an uncleaved trimer, 
which could potentially skew the results.  Recently, a cryo-electron microscopy structure 
has been determined and fit with crystal data to generate a 4.2 angstrom structure [36].  This 
new, cleaved, and fully glycosylated trimer represents the closest structure available to 
visualize a native HIV-1 envelope.  The ability to use the structure to visualize gp120 in 
relation to gp41 is an extremely powerful tool to understand the proteins, their interactions, 
and transitions between different Env states. 
 
1.4.3. The HIV-1 Entry Process 
 
HIV-1 utilizes the envelope glycoprotein trimer to infect immune cells, predominantly 
CD4+ T-cells and cells from the monocyte/macrophage lineage.  The HIV entry process is 
the first viral process involved with infection of host cells.  The process begins when the 
virion’s surface protein complex, Env, comes in contact with a CD4+ cell.  CD4, a member 
of the immunoglobulin superfamily that enhances T-cell receptor signaling, interacts with 
the surface protein gp120 of HIV-1 [37-39], leading to a conformational change that 
establishes a previously masked and unformed bridging sheet motif  [40] and the 
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repositioning of the V3 loop [21, 41].  Formation of the bridging sheet allows the gp120 to 
establish contact with a co-receptor molecule, either CCR5 or CXCR4, on the host cell and 
trigger another conformational change that exposes the fusion peptide of gp41.  The N-
terminus of the co-receptor is specifically responsible for binding to the newly formed 
bridging sheet and the V3 loop is then available to insert itself into a pocket formed by the 
extracellular loops of the co-receptor [39].  The fusion peptide then embeds itself in the host 
cell membrane and a cascade of helices are formed, which ultimately leads to a six-helix 
bundle conformation [42, 43].  The formation of the six-helix bundle results in pulling the 
virus and host cell membrane within close enough proximity to one another, thus enabling 
fusion [44].  A depiction of this process can be seen in Figure 3. 
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Figure 3.  Schematic of the HIV-1 entry process.  The HIV-1 gp120 surface protein 
interacts with the host cell CD4 receptor, which induces a conformational change that 
structures epitopes which bind to the co-receptor.  Binding of the co-receptor produces 
further conformational change that leads to the insertion of the fusion peptide of gp41 and, 
ultimately, to the fusion of both viral and host cell membranes. 
 
 
1.4.4. The HIV-1 Entry Cascade 
 
The HIV-1 envelope protein complex exists in a high energy state that forms after cleavage 
between gp120 and gp41 by the furin-like proteases of the cell [24, 45].  The HIV-1 entry 
process typically proceeds down an energy cascade that leads into a low energy six-helix 
bundle (Figure 4).  The binding of receptors to the envelope proteins and the subsequent 
conformational changes drive the protein complex down this energy landscape (Figure 4).  
In the case of HIV-1, the binding of receptor leads into a lower energy trough, but binding 
to co-receptor is generally needed to provide additional activation energy to drive the 
remaining fusion machinery.  Depending on the type of virus, such as a lab-adapted or 
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primary virus, the amount of energy required can vary tremendously.  This has resulted in 
the ranking of particular virus strains into different tiers [45, 46].  The tiers are ranked based 
on their propensity to negotiate transitions.  The lowest tier, tier 1, will readily move outside 
of the native state and the highest, tier 3, will require substantially more perturbation to 
transition.  Some of these viruses have even been discovered that can even sample these 
conformations on their own [45]. 
 
Inhibitors and antibodies are capable of exploiting this intrinsic metastability of the 
envelope, leading to the neutralization of the virus [47, 48] (Figure 4).  These inactivating 
molecules bind and induce changes that provide the energy to drive the virus down a similar 
or an alternative pathway.  This process is highly similar to a mousetrap, which can be 
sprung by touching the trap in a particular way.  Without all of the necessary components, 
such as a receptive cell nearby, the virus can be triggered to go into a low energy state that 
is unable to infect cells and is therefore inactivated.  
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Figure 4.  Diagram of HIV-1 Envelope energy cascade.  Cartoon showing the transitions 
of HIV-1 Envelope down an energy cascade following receptor binding and leading to 
virus entry (blue).  Depiction of how peptide triazoles (PT) can hijack the metastability of 
Env and cause irreversible inactivation (red). 
 
 
 
1.5.  Peptide Triazole Entry Inhibitors 
 
1.5.1. Discovery of Peptide Triazoles 
 
Peptide triazoles represent a novel class of entry inhibitors possessing activity capable of 
irreversibly inactivating HIV-1.   A majority of current inhibitor classes have potencies in 
the nanomolar range and therefore hold great therapeutic promise [47, 49-53].  The parental 
peptide, 12p1 (Figure 5), was discovered through phage display by screening linear 12 
amino acid peptides against a clade B soluble gp120 to prevent CD4 binding [54].  
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Additional analysis showed that 12p1 was able to prevent interactions with both CD4 and 
17b, a co-receptor surrogate [54, 55].  Therefore, the 12p1 peptide provided a great starting 
scaffold for inhibitor optimization and a unique mode of action to investigate.  The initial 
work by Ferrer and Harrison showed that the tryptophan at the core of the peptide was 
critical and a potential hotspot for the observed potency [54].  The proline residue at position 
6, which is close to the important tryptophan at position 7 of the peptide, was chosen as an 
initial spot of variation due to its proximity to important residues and the ability to 
extensively modify this residue.  By changing the proline to an azidoproline, click 
conjugation, through 3 + 2 cycloaddition, was exploited to attach different moieties onto 
the peptide backbone [56].  A multitude of different substituents were attached and screened 
through surface plasmon resonance (SPR) [51, 52, 56, 57].  The attachment of the ferrocene 
yielded the best binding to a variety of gp120s tested, named HNG-156 [51] (Figure 5).  
HNG-156 retained the ability to block both CD4 and 17b binding and showed nanomolar 
potency in cell infection inhibition assays, compared to the micromolar potency of 12p1 
[51].   
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Figure 5.  Evolution of peptide triazoles.  Depiction of structural changes resulting in 
peptide triazole advancement.  The addition of the azido proline with ferrocene, denoted X 
in the sequence, is highlighted (red). 
 
 
1.5.2. Peptide Triazole Binding Footprint 
 
Understanding how inhibitors bind to their target provides strength towards inhibitor 
design.  Alanine-scanning mutagenesis provided a method to help determine the peptide 
triazole binding footprint on HIV-1 gp120 [58].  Although alanine-scanning mutagenesis 
cannot determine the importance of all residues involved with inhibitor binding, it helps in 
determining a general vicinity and cluster of important residues on the protein.  Residues 
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located around two cavities that span the portion of the protein between the inner and outer 
domain of gp120 were found to impact peptide triazole binding [58].  Specific residues 
surrounding the CD4-binding cavity and the b20-b21 hydrophobic binding pocket (T257, 
D474, E370, R476, and V255) were identified [58] (Figure 6). With the exception of amino 
acids, D474 and R476, which can display conservative mutational variations, all of these 
residues are highly conserved in HIV-1 (> 93 %; according to the Los Alamos National 
Laboratories HIV sequence database).  Three different tiers of mutations were established 
based on the ability to affect peptide binding.  Tier 1 had the most profound effect and was 
comprised of D474 and T257.  E370 and M475 had an intermediate effect and were 
classified as tier 2.  The final tier was represented by V255 and R476, which resulted in 
minor changes in peptide binding.  The spatial arrangement of these residues further 
support their importance to both receptor and co-receptor binding.   The identified footprint 
has been tested through molecular docking analyses of peptide triazoles, which resulted in 
many similar low-energy binding poses [49, 59], and through further mutational investigation 
[49], thereby validating the results obtained and confirming the peptide triazole binding site. 
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Figure 6.  Representation of the peptide triazole binding footprint.  Depiction of tier 1 
(red), tier 2 (orange), and tier 3 (yellow) mutations identified from alanine-scanning 
mutagenesis on a HIV gp120 (3HI1).  Percentages of residue frequency are based on all of 
the sequences available in the Los Alamos National Laboratories HIV Sequence Database.  
Adapted from Tuzer et al. 2013 [58]. Copyright permission granted. 
 
 
1.5.3. Virolytic Peptide Triazoles 
 
Using the peptide scaffold of the most potent peptide at the time, HNG-156, a new class of 
peptide triazoles that inactivate HIV-1 by causing intervirion capsid p24 release was 
established, best represented by KR13 [47, 50] (Figure 7A).  Originally designed for 
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attaching to nanoparticles, these inhibitors were found to independently cause lysis of HIV-
1 [50].  These novel inhibitors bind to gp120 like traditional peptide triazoles and trigger the 
typical gp120 shedding inactivation that is hallmark for these molecules, but they also 
display the enhanced ability to trigger downstream events that ultimately lead to the release 
of the viral capsid from inside the virus and collapse of the virion, a term named virolysis. 
 
Additional studies have demonstrated that the presence of a free thiol group at the C-
terminus of the peptide is required for cell-free lysis activity.  By blocking the thiol with 
an acetamidomethyl group, virolysis was lost, but the inhibitor is able to retain the shedding 
inactivation function of all peptide triazoles, thus demonstrating the importance of the free 
thiol [47]. 
 
Further analysis has shown that the overall distance of the cysteine from the gp120 binding 
pharmacophore is important for the lytic activity of the HIV-1 virion.  The distance was 
elucidated by truncating the molecule one residue at a time, but retaining the free thiol on 
the C-terminus, until p24 release was lost [60].  The approximate necessary distance of the 
pharmacophore to the thiol was 20 angstroms based on the assumption of typical bond 
spacing of peptides [60].  Based on this distance and the knowledge that a free-thiol was 
required for virolysis, the disulfides of Env were mutated to determine whether disulfide 
shuffling was occurring and which disulfides were responsible.  A disulfide at the base of 
the V3 loop and the disulfide of gp41 were identified as critical for virolysis [60].  
Competition experiments with the 2G12 antibody, which binds to a cluster of glycans 
located in close proximity to the V3 disulfide [61], and the fusion inhibitor T20, which binds 
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to the N-heptad repeat of gp41 and prevents six helix bundle formation [62], showed that 
virolysis could be lost in response to these inhibitors [47, 60].  Thus, the V3 disulfide and 
downstream six-helix bundle are important for the virolysis mechanism.  Additional data 
supporting importance of the six-helix bundle formation was achieved by time-dependent 
analysis of the virolysis mechanism.  Although gp120 shedding was observed as early as 
10 minutes, virolysis occurred after 30 minutes of treatment, which is consistent with 
hypothesized timing for HIV entry [47] (Figure 7B).  Antibody epitope exposure provided 
the final confirmation of these data.  Antibodies that bind to epitopes exposed downstream 
in the virus entry and fusion mechanism were readily bound to virus treated with KR13 [47].  
However, viruses treated with a blocked thiol were unable to form these epitopes [47].  These 
data suggest that virolytic peptide triazoles induce the Env trimer to proceed down a path 
similar to virus entry, which results in the collapse of the virion since there is no cell present 
for fusion. 
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Figure 7.  Model of peptide triazole inactivation.  A)  Structure of KR13 demonstrating 
the free sulfhydryl on the C-terminus.  B)  Cartoon depicting the timing for peptide triazole 
induced inactivation.  Peptide-induced gp120 shedding occurs early after treatment, but 
virolysis requires a longer period of time to initiate.  Electron micrographs depict the HIV-
1 virion before (left) and after (right) KR13 treatment.  Modified figure from Rosemary 
Bastian. 
 
 
1.5.4. Macrocyclic Peptide Triazoles 
 
A new class of peptide triazoles has been synthesized, recently, that further overcomes 
potential flaws with the original design. One of the main issues with peptide inhibitors as 
clinical drugs is the propensity for degradation by proteases.  Previously, attempts at 
generating D-peptides were investigated, but the unique conformation of the peptide 
triazole pharmacore made it difficult to build a complete D-peptide that is resistant to 
proteolysis [63].   Another method that has been utilized to overcome proteases is the 
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cyclization of peptides, which changes the peptide bond angles and decreases the ability of 
the peptide to fit into the enzyme’s active site [64].    
 
UM15, a 6-mer peptide that has the important I-X-W pharmacophore and low micromolar 
potency [65], was used as a starting template to synthesize a small and potent macrocyclic 
molecule.  Multiple cyclization approaches were employed to generate a potent inhibitor, 
but only the head-to-tail cyclization of the hexapeptide was able to recapitulate the 
necessary pharmacophore structure [53].  The most potent of these macrocyclic peptide 
triazoles, AAR029B (Figure 8), was shown to both resist proteolysis, retain 
submicromolar neutralization of multiple HIV strains, and induce gp120 shedding [53]. 
 
 
 
 
Figure 8.  Structure of the macrocyclic peptide triazole, AAR029B.  Visual representation 
of the peptide demonstrating its cyclic nature. 
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1.6. Viral Escape Analysis 
 
Despite the effort to understand how and where different classes of peptide triazoles bind 
and actuate inactivating pressure, we still do not completely understand these mechanisms.  
A stochastic approach is to use site-directed mutagenesis of hypothesized residues on the 
target to reveal the mechanism.  However, this relies heavily on finding the proper 
combination of mutations.  Another approach is to utilize the selective pressure asserted by 
the inhibitor itself to drive the evolution of the virus to select a pathway towards resistance.  
Dose escalation of inhibitor through virus passaging provides the methodology for this 
approach and has been used for many different inhibitors [66].  Not only does viral escape 
analysis provide data that could predict clinical resistance, but it can also help determine 
the mechanism for neutralization.  A similar approach has been used for BMS-type entry 
inhibitors that were originally believed to function similar to CD4-mimetics.  Information 
attained through virus escape showed that the inhibitor functioned by blocking Env 
transitions from the native state [66-68].  Therefore, it is potentially an invaluable technique 
for furthering the advancement of inhibitors by understanding how resistance will arise 
based on the inactivating mechanism. 
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Chapter 2:  Generating HIV-1 Escape Mutants to 
Peptide Triazole Entry Inhibitors 
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2.1. Introduction 
 
Viral escape analysis can be a strong tool for the advancement of inhibitors by providing 
information regarding how the inhibitor binds, functions mechanistically, and also provide 
valuable clinical insight regarding resistance.  Peptide triazoles have never been used in 
this type of analysis before.  However, previous mutagenic studies with peptide triazoles 
have been explored to identify amino acid residues in gp120 that could affect binding and 
inactivation [58, 69].  Therefore, we initiated studies to investigate how HIV-1 could escape 
from peptide triazole neutralization and inactivating pressure from two different classes of 
peptides.  The lytic peptide triazole, KR13 [50], remains our most potent inhibitor to date 
and the macrocyclic peptide triazole, AAR029B [53], represents a new class of 
proteolytically stable peptides.  Due to their strong potencies in pseudoviral assays, KR13 
and AAR029B were used in our studies. Both of these peptide triazoles have been shown 
to irreversibly inactivate HIV-1 through gp120 shedding [47, 50, 53], however, KR13 is 
capable of further inactivating the virus by causing release of intervirion capsid protein p24 
and causing virion collapse [50].  This inhibitor combination was also chosen to provide a 
comparison between peptide length, cyclization, and the lysis-inducing free thiol on the 
escape mechanism.  We questioned whether resistance between the two classes would 
differ if the lytic pressure was greater than the overall inactivating pressure of binding and 
inducing gp120 shedding.  If lysis is a major contribution towards KR13 neutralization in 
culture, then it should produce a specific resistance response from the virus.  Alternatively, 
if the pressure was not great enough, then resistance would arise similarly between the two 
classes. 
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2.2. Materials and Methods 
 
2.2.1. Reagents and Viruses 
 
The following reagents were obtained from the NIH AIDS Reference and Reagent 
Program, Division of AIDS, NIAID:  HOS CD4+CXCR4+ Cells from Dr. Nathaniel 
Landau; TZM-bl. cells from Dr. John C. Kappes, Dr. Xiayun Wu and Tranzyme Inc.; 
CEM-GFP cells from Dr. Jacques Corbeil; and pNL4-3 from Dr. Malcom Martin.  The 
pNL4-3 Luc AM pseudotyping backbone plasmid was a generous gift from Dr. John 
Moore.  The HIV-1 NL4-3 virus stock was propagated from the pNL4-3 DNA, received 
from the AIDS Reference and Reagent Program, and was a gift from Dr. Michael Root.  
The expression plasmid for HIV-1 HxBc2 strain Envelope was donated by Dr. Joseph 
Sodroski.  Escherichia coli strains XL-10 gold (Agilent) and Stbl2 cells (Invitrogen) were 
used for propagating DNA.  Thermostable DNA polymerase (PfuUltra™) was obtained 
from Stratagene Inc. (La Jolla, CA).  Phusionâ High-Fidelity Polymerase was purchased 
from New England Biolabs (Ipswich, MA).  Custom-oligonucleotide primers were 
supplied by Integrated DNA technologies (IDT). 
 
2.2.2. Peptide Synthesis 
 
Peptides used for this study were synthesized using a microwave peptide synthesizer (CEM 
Liberty Blue) by stepwise solid-phase peptide synthesis (SPPS) on a Rink Amide Resin 
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(NovaBiochem) as described previously [49, 53].  Briefly, a 9-fluorenylmethoxycarbonyl 
(Fmoc) group was utilized as protection for the α-amino group during coupling steps.  
Fmoc amino acids were purchased from Chem-Impex International, Inc.  Triphenylmethyl 
(Trt) for asparagine, tert-butyl (tBu) for serine and tertbutyloxycarbonyl (Boc) for 
tryptophan were used as protection for the side chain groups. 20% piperidine / 
hydroxybenzotriazole (HOBt) in dimethylformamide (DMF) were used for coupling.  The 
[3+2] cycloaddition reaction with ethenyl ferrocene (Sigma Aldrich) was carried out by an 
on-resin method [49, 51].  Completed peptides were cleaved from the resin by using a cocktail 
of trifluoroacetic acid/1, 2-ethanedithiol/water/thioanisole (4.75/0.1/0.1/0.05 v/v for 0.5 
grams of resin) for 2 hours at room temperature.  The solution containing the crude peptide 
was then concentrated under a gentle N2 stream, precipitated to solid peptide pellets with 
precooled diethyl ether, and centrifuged.  Diethyl ether washing was continued until the 
ether layer was no longer colored.  After washing, the crude peptide pellets were once again 
dried by a gentle N2 stream, dissolved, and purified (to ≥95% purity) using semi 
preparative/preparative C18 RP-HPLC columns (Phenomenex Jupiter 10u C4 300A 250 x 
10 mm, 3 ml/min) by HPLC (Beckmann Coulter, System Gold 126 Solvent Module and 
168 Detector, 280 nm) with gradient between 95:5:0.1 and 5:95:0.1 
water/acetonitrile/trifluoroacetic acid.  Purity was monitored by analytical C18 RP-HPLC 
(Phenomenex Luna 5u C18 100A 250 x 4.6 mm, 1 ml/min).  Mass was confirmed using 
matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF 
MS). 
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2.2.3. Cell Culture  
 
Human osteosarcoma (HOS) cells stably expressing CD4 and CXCR4 (HOS.T4.X4) 
were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM, Cellgro) 
supplemented with 10% heat-inactivated fetal bovine serum (FBS; Gemini Bio-Products), 
2 mM L-glutamine (Invitrogen), 25 mM HEPES (Invitrogen), 100 units penicillin - 0.1 
mg/mL streptomycin (Invitrogen), and 0.1 µg/mL puromycin (Invitrogen).  Human 
embryonic kidney (HEK; ATCC) cells and TZM-bl cells were cultured in DMEM, 10 % 
FBS, 2 mM L-glutamine, 25 mM HEPES, and penicillin-streptomycin.  Cells were kept 
in a 37°C incubator with 5% CO2 for growth. 
 
2.2.4. Production and Purification of Envelope-Pseudotyped Luciferase Reporter 
Viruses 
 
Antiviral assays conducted were performed with envelope-pseudotyped luciferase reporter 
viruses, which were prepared by co-transfecting an envelope deficient provirus with an 
envelope expression vector.  This produces a virus particle that is only capable of a single 
round of infection due to a lack of an envelope gene in the produced viral genome.  The 
process was carried out using a standard protocol [47, 70].  Human embryonic kidney (HEK) 
293T cells were co-transfected with the envelope-deficient pNL4 LUC AM provirus 
plasmid (kindly provided by John Moore) and an envelope expression plasmid specific to 
the assay.  The pNL4 LUC AM plasmid construct has the entire envelope gene removed 
and is supplemented with a luciferase gene for easy quantification of infection based on 
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chemiluminescence from the cleavage of a luciferin salt by the recombinant luciferase 
enzyme [71].  Co-transfection was performed by using 4 µg of envelope plasmid and 5 µg 
of pNL4 LUC AM mixed with a polyethyleneimine (PEI) transfection reagent.  Culture 
supernatants were collected 48 to 72 hours after transfection to obtain pseudotyped 
particles.  The particles were centrifuged to pellet any cells, filtered through a 0.45-µm 
polyethersulfone (PES) filter membrane, and then prepared for gradient purification. 
 
Pseudoviruses were gradient purified to remove potentially contaminating proteins and 
exosomes from the preparations.  Since each of these contaminants could alter the 
quantification in downstream analysis.  A continuous 6-20% iodixanol gradient was used 
for purification of pseudoviruses.  Iodixanol was used because it is a small molecule that 
has a density that is both favorable and gentle for virus separation from vesicles, an 
osmolality identical to blood, and has no toxicity to cells [72].  Gradients were prepared 
within a sterile culture hood using a gradient maker.  Virus supernatant was spun in a 100 
kDa spin concentrator to generate a volume suitable for loading on top of the 10 mL 
gradient.  Following loading the concentrated supernatant containing virus onto the 
gradient, it was centrifuged at 40,000 RPM for two hours at 4°C.  Gradients were then 
removed from the centrifuge and the fractions were collected inside a sterile tissue culture 
hood.  Fractions were tested for the presence of virus by using a sample to infect HOS cells 
and another sample to run in a western blot to probe for gp120 and p24 viral proteins. 
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2.2.5. p24 Enzyme-Linked Immunosorbent Assay (ELISA) for Quantifying Virus 
 
50 ng of monoclonal mouse anti-p24 antibody (ab9071; Abcam) was used to coat each well 
of a high protein binding polystyrene 96-well ELISA plate (Corning) for 2 hours at room 
temperature.  The plate was blocked with 3 % bovine serum albumin (BSA; Research 
Products International) in phosphate buffered saline (PBS).  Antigen was then bound after 
diluting to an appropriate level in 0.5 % BSA to prevent oversaturation.  After binding for 
2 hours at room temperature, the plate is washed three times for 5 minutes with PBS 
supplemented with 0.1% Tween-20 (PBS-T).  A 1:5000 dilution of polyclonal rabbit anti-
p24 antibody (ab63913; Abcam) diluted in 0.5 % BSA was then all applied to each well 
and incubated for 1 hour at room temperature.  The plate was then washed with PBS-T 
three times for 5 minutes.  A 1:5000 dilution of donkey anti-rabbit antibody (NA934V, 
GE) conjugated with horseradish peroxidase was then incubated for 1 hour at room 
temperature.  A solution of o-phenylenediamine (OPD; Sigma-Aldrich) was then added to 
each well and incubated for 30 minutes before determining the optical density on a Tecan 
Infiniteâ F50 plate reader at a 450-nm wavelength. 
 
2.2.6. Infection Inhibition of a Reporter Cell Line with Fully-Infectious Virus 
 
TZM-bl cells were seeded into a 96-well plate at a density of 10,000 cells per well and 
cultured overnight.  HIV-1 strain NL4-3 was incubated with serial dilutions of inhibitor for 
30 minutes at 37°C before adding the mixture to the cells.  The virus was allowed to infect 
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for approximately 24 hours before lysing the cells with 1x Passive Lysis Buffer (Promega) 
and multiple freeze-thaw cycles. 
 
2.2.7. Infection Inhibition of CEM-GFP Cells with Fully-Infectious Virus 
 
Microcentrifuge tubes were seeded with 1x106 CEM-GFP cells.  Fully-infectious NL4-3 
virus was mixed with serial dilutions of inhibitor and added to each tube.  The mixture 
was incubated for 4 hours at 37°C.  Following incubation, cells were gently pelleted at 
1500 RPM in a tabletop centrifuge and washed three times with media.  The cells were 
resuspended in inhibitor containing media after the final wash and the culture was split 
into two wells on a 48-well plate.  Virus was allowed to propagate for 6 days.  Viral 
supernatant was then collected, diluted, and measured using a p24 ELISA.  An uninfected 
well and a PBS-treated well served as negative and 100% infection controls, respectively. 
 
2.2.8. Infection Inhibition of HOS Cells with Envelope-Pseudotyped Virus 
 
HOS.T4.X4 cells were seeded at a density of 7,500 cells per well in a 96-well plate.  After 
allowing for overnight growth, pseudovirus stocks that were normalized based on p24 
levels were incubated with serial dilutions of inhibitor for 30 minutes at 37°C before 
applying to the cells.  The media was changed to remove uninfected cells and leftover 
inhibitor after 24 hours.  The cells were allowed to grow for an additional 24 hours to allow 
production of the luciferase protein.  Cells were then washed with PBS and lysed with 
Passive Lysis Buffer (Promega) and multiple freeze-thaw cycles.  An uninfected well and 
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a PBS-treated well served as a background and 100% infection control, respectively.  
Infection was quantified by a luciferase assay. 
 
2.2.9. Luciferase Assay for Measuring Viral Infection  
 
A portion of the lysate from the infection inhibition assay was transferred into a 96-white 
well plate.  A luciferase buffer was then added to each well containing 15 mM KPO4, pH 
7.8; 15 mM MgSO4, 1 mM ATP, and 1 mM DTT.  D-Luciferin salt (Anaspec) was used as 
a substrate for the luciferase enzyme.  Detection was performed on a GloMax-96 Plate 
Luminometer (Promega).  Non-linear regression analysis was performed using OriginPro 
8.1 (Origin Lab, Northampton, MA). 
 
2.2.10. Origin Pro 8.1 Curve Fitting of Dose-Dependent Data 
 
Data analysis of dose-dependence measurements were performed using the sigmoidal 
logistic curve fitting function in OriginPro 8.1 (Origin Lab, Northampton, MA) software. 
The formula used is represented by the following equation: 
 
𝑦 = 𝐴$ − 𝐴&1 + 𝑋𝑋* + + 𝐴& 
 
where A1 is the initial value, A2 is the final value (based on the experimental data), p is the 
Hill coefficient, x is the concentration of the inhibitor used and X0 is the IC50 value. The 
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logistic nature of the fitting algorithm allows the p value to float freely.  The observed 
differences in cooperativity between the fitted plots likely arise from complexities of the 
different interactions between the inhibitors, the viruses, and the cells. 
 
2.2.11. Passaging of Fully-Infectious Virus with Inhibitor Dose Escalation 
 
Fully-infectious NL4-3 virus was used for virus passaging studies.  Virus stocks used to 
initiate the study were a gift from Michael Root.  Passaging in the presence of inhibitors 
was performed using a previously published protocol [73] and started at the determined IC50 
value of the inhibitor with NL4-3 virus culture supernatant.  Culture supernatant was 
routinely collected and lysed with Triton X-100, either weekly or biweekly, to determine 
the amount of p24 present in the supernatant.  The level of p24, determined by p24 ELISA 
[47], was dependent on the amount of virus able to be produced in the culture.  When the 
level of p24 in peptide-treated cultures was greater than or equal to the amount in untreated 
control cultures, then the concentration of inhibitor in the culture was escalated 
approximately two-fold. 
 
Culturing was carried out in 48 well plates using CEM-GFP cells, an immortalized T-cell 
line that expresses green fluorescent protein in response to HIV infection [74], as the target 
cells for virus infection.  Three separate cultures were used for each treatment.  Each plate 
only contained one treatment to prevent virus contamination between sample groups.  PBS 
was also added to each plate between samples to provide a barrier between cultures and to 
prevent evaporation. 
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Virus cultures were passaged each week by transferring 100 µL of culture supernatant  onto 
0.5x106  freshly-prepared CEM-GFP cells in 500 µL of CEM medium (RPMI 1640, 10% 
Fetal Bovine Serum, 1% 100x penicillin-streptomycin, 1% 200 mM L-glutamine, and 500 
µg/mL G418).  After inoculating the culture each week, the remaining supernatant was 
made into 2 aliquots and frozen at -80°C.  The cell pellet was then resuspended in PBS and 
frozen at -80°C in preparation for genomic DNA (gDNA) isolation. 
 
2.2.12. Purification of Genomic DNA from Infected Cells 
 
Previously frozen cells for the desired week were removed from the -80°C and thawed at 
room temperature.  Genomic DNA from infected cells were obtained using the QIAamp 
DNA Mini and Blood Mini Kits (Qiagen) and following the manufacturer’s protocols.  
Briefly, cells were lysed using basic conditions and mechanical agitation in the presence 
of RNAse I.  After neutralization, the DNA was bound to Qiagen spin columns and washed 
twice before eluting DNA.  DNA was then measured on a NanoDrop 1000 to monitor 
purity and to measure concentration. 
 
2.2.13. Design of PCR and Sequencing Primers 
 
Primers were designed using Primer3 software [75].  Using the available subtype B 
sequences in the Los Alamos National Laboratory HIV Database, the sequences were 
aligned and used a 90% threshold cut off for homology.  Three primer sets were designed 
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to cover the Env gene of HIV-1.  Penalties for non-conserved regions of the genome were 
assigned to drive sets of primers with universal binding capability.  Only regions with 
highly conserved nucleotide sequences were utilized.  Each primer set was designed to 
have a similar melting temperature of approximately 60°C to allow for compatibility and 
to enable reactions to be performed simultaneously.  The primer sets were:   
1.) 5’-CCATACATTATTGTGCCCCG-3’ (Forward)  
     5’-AGGTATCTTTCCACAGCCAG-3’ (Reverse)  
2.) 5’-GGAAGCATCCAGGAAGTCAG-3’ (Forward)  
     5’- GCTAGACTGCCATTTAACAGC-3’ (Reverse)   
3.) 5’- GAGAAGAGTGGTGCAGAGAG-3’ (Forward)  
     5’- GTCCCAGAAGTTCCACAATC-3’ (Reverse) 
 
2.2.14. Amplification of the HIV-1 Genome 
 
The HIV-1 genome was amplified using the specific PCR primers mentioned above.  Each 
primer set generated an approximately 1 KB fragment that overlaps with another PCR 
fragment to ensure coverage of the genome.  Amplification was accomplished using the 
Phusionâ High-Fidelity polymerase system (New England Biolabs).  The reaction mixture 
was optimized for these primer sets as follows: 1x High Fidelity buffer, 2.5 mM MgCl2, 
0.35 mM dNTP mix, 0.3 mM of a pair of forward and reverse primers, and 0.5 units of 
Phusionâ High-Fidelity polymerase.  The reaction was initiated with a 2 minute initial 
denaturation at 95°C, followed by for 40 cycles of amplification (94°C for 30 seconds, 
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58°C for 30 seconds, and 72°C for 1 minute), and a final elongation step of 72°C for 10 
minutes.   
 
Following the PCR reactions, samples were analyzed by agarose gel to confirm a single 
band at the correct fragment size.  The gel was prepared as a 1% agarose gel in 1x TAE 
buffer (40 mM Tris, 20 mM acetic acid, and 1 mM EDTA) and was run in 1x TAE buffer 
at 100V until the desired migration was achieved.  The gel was then stained with ethidium 
bromide and visualized using UV light to confirm the proper size. 
 
2.2.15. Purification of HIV-1 PCR Fragments 
 
PCR fragments of the amplified HIV-1 genome were purified to remove contaminating 
reagents, such as salt and unused dNTPs, that will interfere with sequencing.  The Wizardâ 
SV Gel and PCR Clean-Up System (Promega) was utilized for this purification step by 
following manufacturer’s protocols for the kit.  Briefly, the PCR reaction was diluted in 
buffer to optimize binding to the column.  The mixture was loaded onto the column, washed 
to remove impurities, and eluted with nuclease-free water. 
 
2.2.16. Traditional Sanger Sequencing of HIV-1 Fragments 
 
The cleaned PCR samples were sequenced through traditional Sanger sequencing by 
Genewiz, LLC.  Each sample was prepared according to guidelines established by 
Genewiz.  20 ng of DNA was combined with 2.5 pmol of the forward primer corresponding 
	 37	
to each fragment and then the volume was adjusted with nuclease-free water.  Samples 
were shipped to Genewiz and each sample was subjected to Sanger sequencing by capillary 
electrophoresis.  Each sequencing run was analyzed to confirm it passed a specific quality 
threshold, that is based on a quality score (QS) of at least 30 and a contiguous read length 
(CRL) of at least 500, established by Genewiz.  The QS is the average of the quality values 
(QV) for each base from the sequencing.  It is derived from the following formula, where 
PE is the Probability of Error: 
 
QV = -10log10(PE) 
 
Samples that did not meet the threshold were resequenced until an appropriate QS and CRL 
was achieved.  A QS of >40 was automatically passed and a score of 30-39 was manually 
reviewed to ensure a good trace result.  A QV of 30 corresponds to a probability of error 
of 0.1%. 
 
2.2.17. Alignment of HIV-1 Sequences 
 
Sequences obtained from Genewiz were compiled based on which sequencing primer was 
used for analysis.  The proper in frame codons were determined and the genomic 
sequencing data was converted to protein sequences using Serial Cloner 2-6-1 (Serial 
Basics software) and made into FASTA format.  After conversion, protein alignments were 
completed using the Clustal Omega (EMBL-EBI) online software.  Wild-type NL4-3 and 
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HxBc2 sequences, as well as week 0 culture sequences, were used for reference and to rule 
out any potential mutations present from the start of virus culturing. 
 
2.2.18. Site-Directed Mutagenesis 
 
The HxBc2 envelope expression plasmid was used for site-directed mutagenesis due to a 
lack of NL4-3 envelope expression plasmid and a 97% homology between the strains.  
Mutations were introduced using the Quik-change site-directed mutagenesis reagents and 
methods (Stratagene).  Primers were designed and their reverse complement were 
synthesized by IDT using solid phase synthesis.  The following primers were used: 
R476K Forward   
5’- GGAGGAGGAGATATGAAGGACAATTGGAGAAGTG -3’ 
R476K Reverse  
5’- CACTTCTCCAATTGTCCTTCATATCTCCTCCTCC -3’ 
V255I Forward  
5’- GGAATTAGGCCAGTAATATCAACTCAACTGC -3’ 
V255I Reverse  
5’- GCAGTTGAGTTGATATTACTGGCCTAATTCC -3’ 
V255T Forward  
5’- GGAATTAGGCCAGTAACATCAACTCAACTGC -3’ 
V255T Reverse  
5’- GCAGTTGAGTTGATGTTACTGGCCTAATTCC -3’ 
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S143N Forward  
5'-GATACTAATACCAATAGTAATAGCGGGAGAATGATAATG-3'  
S143N Reverse  
5'- CATTATCATTCTCCCGCTATTACTATTGGTATTAGTATC -3' 
 
Mutations were transformed into XL-10 gold cells and DNA was isolated using a 
PureYield Plasmid Miniprep kit (Promega) and sequenced by Genewiz.  Confirmed 
mutants were transformed into MAX Efficiency Stbl2 cells (Stratagene) to better support 
the retrovirus vector and purified using a Hispeed® Plasmid Maxiprep kit (Qiagen).   
 
Double mutations were made using the purified and sequenced DNA from a single mutant 
as a template for another round of site-directed mutagenesis.  They were transformed and 
purified using the same protocol listed above for the single mutations and sequenced to 
confirm that both mutations were present. 
 
2.2.19. Molecular Modeling of the Peptide Triazole Binding to a Fully-Glycosylated 
HIV-1 Trimer 
 
Peptides were first prepared for the docking study in silico by using the ligand building 
tool of The Schrödinger package (Schrödinger Suite 2014; Schrödinger, LLC). These 
minimized structures were saved as pdb files for use in the docking simulations. Autodock 
tools graphical interface (MGtools 1.5.6rc3) [76, 77] was then used for final preparations of 
the peptides for docking. 
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UM15 conformational sampling was performed by means of 100 ns MD simulation in 
explicit solvent by means of NAMD 2.10, using the same parameters as described above. 
The 100 ns trajectory was then clustered on the peptide heavy atoms excluding the 
ferrocenyl moiety, using the linkage algorithm, setting 0.11 as threshold cutoff, by means 
of GROMACS 5.0.4. Twelve clusters were obtained, and the most representative structure 
of each cluster was then subjected to flexible docking. 
 
In preparation for flexible docking, the Schrödinger package (Schrödinger Suite 2014; 
Schrödinger, LLC) was used for repairing the protein structure (chain A form the trimer 
structure pdb code 5FUU) with the protein preparation wizard in Maestro 9.9 where the 
missing side chains were added and refined. The repaired protein structure was then 
prepared by Autodock tools graphical interface (MGtools 1.5.6rc3) where non-polar 
hydrogens were merged, Kollman charges added and Gasteiger charges were calculated.  
Tryptophan 112 and Tryptophan 427 residues were set as flexible for the docking where 
the indole side chain can move during the docking simulation to uncover the hydrophobic 
pocket in the inner domain gated by this residue, as we previously showed [49]. The grid 
box for the docking search was set to 52 x 52 x 52 points for the x, y and z dimension with 
a spacing grid of 0.375 Å.  We utilized the AutoGrid 4.2 algorithm to evaluate the binding 
energies between the peptide and the protein to generate the energy maps for the docking 
run.  The maximum number of evaluations (25,000,000) was used with the protein in high 
accuracy mode for the peptides. Fifty runs were generated for each peptide by using 
Autodock 4.2 Lamarckian genetic algorithm [76, 77] or the searches. Cluster analysis was 
	 41	
performed on docked results, with a root-mean-square tolerance of 2.0 Å. Visual inspection 
of the lower energy docked poses was compared to the prior modeling work with the 
monomeric gp120 [49] and taking into consideration the mutagenesis analyses results, 
lowest binding energy poses that matched the mutational and structure activity analyses [49] 
were selected as a representative complex for each compound. The complex was then 
visualized by VIDA 4.2.0 (Openeye Scientific Software, Santa Fe, NM. 
http://www.eyesopen.com).  Conformers returned from docking with high binding energy 
(positive values) were excluded. The lowest binding energy pose among the remaining 
conformers, that also matched the mutation data, was selected as a representative binding 
mode.  
 
2.3.  Results 
 
2.3.1. Calibration of Inhibitor Concentrations for Dose Escalation 
 
Determination of the potencies of each of these inhibitors on replication competent wild-
type NL4-3 virus was performed to provide insight regarding the necessary concentrations 
for the dose escalation analysis.  KR13 and AAR029B demonstrated strong antiviral 
potencies (IC50) of 78 nM and 271 nM, respectively, in a TZM-bl reporter assay (Figure 
9).  These results correlate well to the values obtained in pseudoviral assays reported 
previously [50, 53, 69].  We also confirmed the potencies of these inhibitors with CEM-GFP 
cells, which are used in our passaging experiment, to ensure that each inhibitor neutralizes 
virus regardless of the cell line used (Figure 10).  AAR029B neutralization on CEM-GFP 
	 42	
cells was performed only once and displayed a higher value than expected, but monitoring 
the early passaging cultures showed that the virus was indeed susceptible to neutralization 
at the expected concentration. 
 
 
 
 
 
Figure 9.  Infection inhibition of fully-infectious NL4-3 with peptide triazole entry 
inhibitors.  TZM-bl reporter cell assay with AAR029B and KR13 displays low nanomolar 
potency against the fully-infectious HIV-1 strain, NL4-3.  Error bars represent the standard 
deviation of the mean, n=3. 
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Figure 10.  Infection inhibition of a fully-infectious HIV on a T-cell line by peptide 
triazoles.  Both, AAR029B and KR13 are able to neutralize fully-infectious NL4-3 on the 
T-cell line, CEM-GFP.  Error bars represent the standard deviation of the mean, n=2 for 
KR13 and preliminary data for AAR029B, n=1. 
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2.3.2. Dose Escalation 
 
A preliminary dose escalation experiment was carried out to establish the technique and to 
begin passaging while enough inhibitor was prepared for the comparative study.  KR13 
was used for this experiment since we had a surplus of inhibitor to test.  HIV-1 strain NL4-
3 was serially passaged on CEM-GFP cells under increasing inhibitor concentrations, 
starting at inhibitor levels approximately half of the observed IC50 concentration from the 
TZM-bl assays.  Dose escalation was carried out to allow virus to evolve and escape peptide 
triazole pressure.  The passaging was continued until the cultures were growing at an 
appreciable level (>100x the starting culture concentration), which was roughly six months 
(Figure 11).  This level of resistance demonstrates that the virus is able to propagate under 
these culture concentrations, but it does not necessarily mean that resistance from the 
mutations will correlate in a single round assay.  A variety of other factors, such as cell-to-
cell transmission, are possible under the culturing conditions.  Two separate cultures of 
KR13 were run in parallel.  One of the cultures was at approximately the IC50 value 
(Culture 1) and another was half of that concentration (Culture 2).  This was necessary 
because an initial attempt at passaging at the IC50 resulted in the death of all virus in the 
treated cultures. 
 
When sufficient levels of both KR13 and AAR029B were achieved, we initiated another 
dose escalation study to compare the resistance profiles for each inhibitor.  The experiment 
was carried out with both inhibitors using the established protocol from the preliminary 
experiment with NL4-3 virus and CEM-GFP cells.  Peptide triazole concentrations were 
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increased until each of the cultures was growing in approximately 250 times the starting 
inhibitor concentrations (16 µM for KR13 and 125 µM for AAR029B).  Escalation of 
culture inhibitor concentrations continued for 4 months in order to achieve this level of 
resistance (Figure 12).   
 
An initial lag in resistance development was observed for peptide triazole-treated cultures.  
It took five to six weeks for each of the inhibitor-treated cultures to begin to show signs of 
resistance in the preliminary and comparative study, respectively (Figures 11 and 12).   A 
control culture of C37, a gp41-targeting fusion inhibitor [78], was initially performed with 
the NL4-3 virus as a reference for resistance since the escape profile was already 
established.  C37 resistance occurred immediately in the culture whereas there was a delay 
associated with peptide triazoles.  After the delay, a sharp increase in culture resistance 
was observed for both classes of peptide triazoles.  
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Figure 11.  Dose-escalation of inhibitor concentrations during preliminary virus passaging 
experiment.  The resistance ratio is the ratio between the weekly culture concentration and 
the initial inhibitor concentration.  Culture 1 was started at approximately the IC50 and 
Culture 2 was started at half that value. 
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Figure 12.  Dose-escalation of inhibitor concentrations during virus passaging of both 
peptide triazole classes.  The resistance ratio is the ratio between the weekly culture 
concentration and the initial inhibitor concentration.  C37 was used as a control because 
the kinetics of resistance were known to occur rapidly in a well-defined manner.  Peptide 
triazole resistance developed similarly and after an initial delay.  Error bars represent the 
standard deviation of the mean between the three cultures for each inhibitor at that time 
point. 
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2.3.3. Sequence Tracking of Env Protein Complex During the Course of the 
Preliminary Passaging Experiment 
 
To provide a snapshot of the mutations present in each culture, genomic DNA samples 
from the infected CEM-GFP cells from three time points were isolated.  The three time 
points were selected based on the passaging growth curve.  Weeks 5, 15, and 25 were 
chosen from the preliminary experiment because these points are representative of the 
beginning, middle, and end of the resistance growth progression, respectively.  Multiple 
primer pairs spanning the entire HIV-1 Env were then used to amplify segments of the gene 
by PCR.  These amplified genomic samples subsequently analyzed by traditional Sanger 
sequencing.  A sample of the virus culture used to initiate each of the treated and untreated 
cultures was sequenced as a reference and to confirm that there were no unanticipated 
mutations at the start of the experiment.  Mutations present in both the untreated control 
cultures and the peptide-treated cultures were disqualified in the analysis as they did not 
arise from peptide triazole selective pressure. 
 
The viral sequences were aligned based on the week of passaging to determine which 
mutations were present at each time point.  Each of the cultures developed a different set 
of resistance mutations.  Only a few different mutations developed at the beginning of the 
passaging, but the envelope became more decorated as the passaging continued (Table 1).  
Of note, at week 5, Culture 1 developed an early mutation along the gp120-gp41 interface 
with a V84A mutation and Culture 2 produced a V255I mutation that is within the CD4 
and peptide triazole binding sites.  Culture 2 also evolved a T297I mutation, which is in 
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very close proximity to the V3 disulfide.  By the end of passaging at week 25, there were 
two novel mutations that were shared between both cultures (N301K and R476K).  Culture 
1 also produced a S375N mutation, which is an important peptide triazole binding residue 
and located within the CD4 binding site [47, 79].  Another interesting mutation from week 25 
was a S465P mutation in Culture 2, which can affect CD4 binding [80].  Similar to the V84A 
mutation observed in Culture 1, Culture 2 developed a mutation (A525T) along the 
interface at week 25, pointing to the potential importance of this epitope.   
 
 
 
 
Table 1.  Summary of mutations identified in the preliminary passaging study.  Each 
mutation observed was organized based on culture and time point.  Env protein features 
are labeled on the left for reference.  * denotes that E464 is the wild-type residue of HxBc2 
at this position. 
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2.3.4. Sequence Tracking of Env Protein Complex During the Course of the 
Comparative Passaging Experiment 
 
The same genomic DNA isolation procedure, sequencing protocols, and mutational 
analyses established in the preliminary experiment were carried out for the comparative 
resistance study.  Three time points were selected from the comparative study based on the 
same rationale in section 2.3.3, which resulted in harvesting samples from weeks 6, 10, and 
15.   
 
Alignment of the viral sequences from the various time points for both inhibitors indicated 
that early resistance was attributed to a single mutation (S143N) located in the variable 
loop region 1 of gp120, which disrupts a potential N-linked glycosylation site at the apex 
of the trimer.  By week 10, another prominent mutation was observed within all of the 
peptide-treated cultures at position 255 of gp120.  V255 is highly conserved, with over 
97% homology, according to the sequence alignments of the HIV-1 genomes in the Los 
Alamos National Laboratories Database.  The V255I mutation was observed in all cultures 
except one, KR13 Culture 1 (Table 2).  In this particular culture, a V255T mutation was 
present instead.  An arginine to lysine mutation of residue 476 was found in a few cultures 
but did not persist in most of these cultures at the end of passaging.  Hence, only two 
prominent mutations were observed in all of the resistant cultures treated with peptide 
triazoles, S143N and V255I/T. 
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A deeper analysis of trace data from the comparative sequencing runs showed that 
quasispecies existed at some residues.  The S465P mutation was also identified from the 
preliminary experiment.  In addition, the V87A mutation is located within the same gp120-
gp41 interface as the V84A mutation seen in Culture 1, suggesting a similar resistance 
mechanism. 
 
 
 
 
Table 2.  Summary of mutations identified in the comparative passaging study.  Each 
culture shown was independent and separated by week.  Labels above mutation represent 
the wild-type sequence at that position.  Black dots represent no change in sequence. 
 
 
2.3.5. Site-specific Mutations in Envelope-Pseudotyped Virus Background  
 
Based on mutations identified in the HIV-1 viral genome that were induced in the presence 
of peptide triazoles, the next aim was to further investigate how these particular mutations 
contribute to the HIV-1 virus phenotype to escape neutralization from the peptide triazoles.  
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Specific single and double mutations identified during virus passaging were incorporated 
by site-directed mutagenesis to assess the impact of each mutation and combination on 
peptide-induced inhibition.  The resultant envelope-pseudotyped viruses were tested in 
infection inhibition assays to determine their sensitivity to the peptide triazoles. Only 
mutations from the comparative study were selected for analyses because similar mutations 
were observed in both studies and comparison of the two peptide classes was a main goal 
of the project. 
 
Each of the three mutations was incorporated individually into a pseudotyped virus with a 
mutant Env to determine its distinct contributions towards resistance.  We also generated 
the double mutants of S143N and V255T since these mutations developed and persisted 
together in every peptide-treated culture, which resulted in steep resistance growth 
following their co-evolution.  We attempted to generate the S143N/V255I double mutant, 
but additional mutations developed during the transformation and DNA purification step, 
which resulted in a virus sample that was unfit for analysis.  We will be investigating the 
S143N/V255I double mutant to ensure similar results are observed.  HxBc2 envelope-
pseudotyped virus was utilized as a surrogate strain due to availability.  HxBc2 shares a 
97% sequence homology with NL4-3 and both strains are X4-tropic, clade B, and lab-
adapted.  More importantly, there was no difference between the wild-type viruses of 
HxBc2 and NL4-3 at the resistance residues identified from the escape study. 
 
The single mutant harboring the early mutation observed in all cultures, S143N, showed a 
minor change in peptide triazole neutralization sensitivity for both KR13 and AAR029B 
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(Figures 13 and 14) by 58-fold and 1.5-fold, respectively, as compared to the wild-type 
virus (Table 3).  The 58-fold change for S143N seems very high for KR13, but the wild-
type HxBc2 neutralization resulted in a substantially lower IC50 than normal (~5 - 50 nM). 
However, the individual V255 mutations exhibited a much more pronounced shift in 
neutralization corresponding to approximately 3800- and 26-fold change in potency 
(Figures 13 and 14; Table 3).  R476K mutant pseudovirus yielded a minimal loss in 
potency similar to that observed with S143N (Figures 13 and 14; Table 3). 
 
The double mutant of S143N and V255T provides a better representation of the resistant 
virus from the cultures since both mutations were observed in the peptide-treated cultures 
starting from week 10 and a similar mutation pair was observed in the preliminary 
passaging experiment.  When an infection inhibition assay was performed with the 
S143N/V255T mutant envelope-pseudotyped virus, the loss of potency was observed to be 
similar to that of the single V255T mutant (Figures 13 and 14). 
 
The results from the infection inhibition assays display two different tiers of sensitivity to 
the mutations.  The first tier of sensitivity corresponds to a minor increase in resistance, 
which is comprised of the S143N and R476K mutations.  These mutations cause an 
approximate 50- to 2-fold change, to KR13 and AAR029B, whereas a second tier of 
mutations, which are represented by the V255 single mutants and the double mutants result 
in a greater than 3500- and 25-fold change.  The difference in fold change between the 
peptide classes in response to these mutations suggests that they bind differently to the 
protein, which is likely a result of the cyclization, despite using the same cavities. 
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Figure 13.  KR13 neutralization of mutant envelope-pseudotyped viruses.  Individual and 
combinational envelope-pseudotyped viruses were analyzed for their resistance to KR13-
associated infection inhibition.  Error bars represent the standard deviation of the mean 
between different experiments, n=3.  
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Figure 14.  AAR029B neutralization of mutant envelope-pseudotyped viruses.  Individual 
and combinational envelope-pseudotyped viruses were analyzed for their resistance to 
AAR029B-associated infection inhibition.  Error bars represent the standard deviation of 
the mean between different experiments, n=3. 
 
 
 
 
	 56	
Virus KR13 
IC50 (nM) 
Hill 
Coeff. 
n-fold* AAR029B 
IC50 (µM) 
Hill 
Coeff. 
n-fold* 
Wild-type 0.134 ± 0.007 0.40 - 0.575 ± 0.154 0.75 - 
S143N 7.83 ± 4.77 0.90 58.4 0.881 ± 0.267 0.87 1.5 
R476K 9.94 ± 6.54 0.64 74.2 1.59 ± 0.391 0.71 2.8 
V255I 517 ± 115 0.85 3858.2 14.9 ± 8.27 1.44 25.9 
V255T 1409 ± 568 1.77 10514.9 19.4 ± 2.70 1.85 33.7 
S143N/V255T 1654 ± 371 1.21 12343.3 25.1 ± 3.46 2.01 43.7 
 
Table 3.  Resistance profiles of selected mutations.  Summary of pseudoviral analysis from 
mutations selected from peptide triazole passaging. The Hill coefficient relates to the slope 
of the curve and demonstrates cooperativity (>1 is positive, <1 is negative, and 1 is 
noncooperative).  *n-fold refers to the fold-change from wild-type pseudovirus. 
 
 
2.3.6. Infectivity Effects of Mutations Arising During Passaging 
 
We have identified two different types of mutations in the virus, inside and outside the 
binding site. Next, we wanted to understand the impact these resistance mutations have on 
the overall infectivity fitness of the virus.  Resistance mutations that decrease viral fitness 
are clinically meaningful because they demonstrate that the virus must compromise its 
well-being in order to evade neutralization.   
 
Since peptide triazoles bind at crucial spots on gp120 that are necessary for the overall 
infectivity of the virus, we used the mutant envelope-pseudotyped viruses generated to 
investigate changes in infection potential.  The prepared viruses were normalized based on 
p24 and allowed to infect target cells without the selective pressure of peptide triazoles.   
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Of the mutants tested, S143N and R476K displayed infection similar to wild-type levels 
and were not found to be significantly different by a student’s two-tailed t-test (Figure 15).  
It is not surprising that mutations at position 255 resulted in a decrease in infectivity given 
their importance with CD4 binding [80, 81].  However, the threonine mutation induced a more 
profound decrease in infectivity compared to the isoleucine mutation (Figure 15).  In this 
case, it was the double mutation of S143N/V255T that generated the greatest overall 
change from wild-type (Figure 15).  Surprisingly, this mutational combination resulted in 
a more than two-fold increase in infection suggesting that these mutations alter the virus.  
We were able to demonstrate the main mutation responsible for resistance to peptide 
triazoles comes at a cost for viral infectivity.  Nonetheless, the virus can utilize additional 
mutations to counteract this deficit.  
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Figure 15.  Infectivity of enveloped-pseudotyped viruses is altered by peptide triazole 
resistance mutations.  Envelope-pseudotyped viruses were normalized based on p24 and 
allowed to infect HOS.T4.X4 cells.  Error bars represent the standard deviation of the mean 
between different experiments, n=3.  p = 0.028, 0.0027, and 0.0059 for V255I, V255T, and 
S143N/V255T, respectively; Student’s two-tailed t-test. 
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2.3.7. Correlation of Resistance Mutations with Docked Models of Peptide Triazoles 
with gp120 in the Env Trimer 
 
Since the prominent mutations resulting in resistance rested in the peptide triazole binding 
site, we performed flexible docking of a peptide triazole into the trimer structure in the 
presence and absence of the V255I mutation to confirm its effects.  We utilized the short 
linear peptide triazole, UM15, which contains the important I-X-W pharmacophore (X= 
azidoproline with a ferrocene) and has previously served as a template for peptide design 
[49, 53, 65].  UM15 has been used for previous docking studies and its binding characteristics 
have been extensively investigated [49].  Docking with UM15 on wild-type trimer (5FUU) 
resulted in a low energy conformation that aligns very well with previous docking and 
experimental data (Figure 16).  The 5FUU trimer is a recently solved structure that was 
obtained through cryo-electron microscopy (cryo-EM) of a cleaved and fully-glycosylated 
JR-FL Env trimer bound to PGT-151 [36].  The cryo-EM structure was reconstructed using 
the available PGT151-bound BG505 SOSIP trimer structures (4TVP and 4NUG) [36].  
Residues that are characteristic for the two binding cavities are highlighted in red (Figure 
16A).  E370 and S375 are typical residues found lining the CD4 binding subcavity one [49].  
The hydrophobic pocket, subcavity two, highlighted with the residue W112 in Figure 16, 
is critical for forming the bridging sheet essential for co-receptor binding in normal HIV 
entry.   The important V255 residue is located on a b-turn between the two cavities and has 
been colored yellow for reference. 
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In silico mutagenesis of residue 255 to isoleucine and threonine was created in the UM15-
docked trimer (Figure 17).  The additional methyl group or hydroxyl group for isoleucine 
and threonine, respectively, produced many rotamers that had steric clashes with the 
ferrocene group of the peptide triazole.  Therefore, these mutations are likely disrupting 
peptide triazole binding by sterically occluding entry into this crucial cavity.  
 
To investigate this hypothesis, an additional flexible docking experiment was performed 
with a V255I trimer to investigate whether there would be a docking defect associated with 
this mutant (Figure 18).  The resultant lowest energy poses for this experiment yielded 
conformations where the peptide was not sitting inside either pocket, but was on top of the 
cavities.  The poses for V255I are also not consistent with prior data [49, 59].  Therefore, it 
provides validation that the mutation to isoleucine can potentially disrupt docking into the 
essential binding cavities of gp120.  
 
Overall, our data suggest that the V255I/T mutations were most critical for peptide triazole 
escape.  Since mutations were similar between the two classes of peptides, the selective 
pressure of the thiol during this experiment was not enough to direct the virus down an 
alternative resistance pathway from the non-lytic peptide.  In conclusion, the data 
demonstrate that escape to KR13 and AAR029B can form by filling in the crucial binding 
pockets occupied by the peptides during neutralization and therefore prevent all events of 
viral inactivation. 
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Figure 16.  Flexible docking of a linear peptide triazole into an HIV-1 trimer shows the 
proximity of V255 to an important peptide moiety.  A:  Docking of UM15 (INNIXW) into 
an HIV-1 trimer (5FUU) with important residues highlighted.  Red residues are 
characteristic of the binding cavities.  V255 is highlighted in yellow.  B:  Contact map of 
UM15 in the 5FUU trimer.  V255 is marked with a star to display its close proximity to 
ferrocenyl.  
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Figure 17.  in silico mutagenesis of V255 shows steric clashes with the ferrocenyl moiety 
of peptide triazoles.  V255 (orange) of the HIV-1 trimer (5FUU) was mutated to isoleucine 
(red) and threonine (yellow) in the wild-type docked with UM15 structure. 
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Figure 18.  Flexible docking of UM15 into V255I HIV trimer is disrupted.  Isoleucine 255 
(red) was generated in silico into the HIV-1 trimer (5FUU) and was used as a starting 
structure for flexible docking.  The peptide sits on top of structure instead of burying itself 
as observed with the wild-type trimer. 
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2.4.   Discussion 
 
Drug resistance to current HIV therapy is an emerging problem facing the HIV field.  
Understanding how resistance arises and developing better inhibitors to overcome this 
issue is paramount.  In this present study, we sought to develop a resistance profile for 
HIV-1 escape from peptide triazole entry inhibitors in order to better comprehend their 
mechanism of action and to assist with the optimization of the overall inhibitor scaffold.  
While the inhibitors used in this study are not currently ready for clinical application, the 
knowledge obtained has shed new light on the importance of particular elements on both 
the target protein complex and the inhibitors themselves.  It has also provided insight 
regarding how to potentially modify the inhibitors to increase the threshold for resistance 
development.  This work showed that mutations developed throughout Env, in both the 
binding site and areas potentially critical for the peptide triazole mechanism of action, to 
allow the virus to evade neutralization. 
 
We initiated this investigation to identify how resistance would develop between the 
individual peptide triazole classes given the functional differences between them, such as 
the lysis-inducing free thiol of KR13 [47, 50] and the truncated and cyclic nature of 
AAR029B [53], in hopes that they would provide mechanistic comprehension about peptide 
function when compared together.  Interestingly, both of the inhibitors displayed nearly 
identical mutational patterns for resistance in this study.  However, they responded 
differently to these mutations.  The V255 mutations had a more profound effect on KR13 
than AAR029B.  This may be due to the cyclic peptide adopting a more stabilized 
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conformation inside the binding pocket than the linear, due to the constrained nature of the 
peptide that is slightly less affected by mutation.   
 
The development of similar mutations may not always happen, as each passaging 
experiment may result in a collection of different mutational patterns.  Despite the potential 
for different patterns from each experiment, important mutational signatures that are 
dependent on the selection pressure will develop within each study.  The preliminary 
passaging study demonstrates this concept by displaying a slightly different resistance 
pattern between the two cultures and the comparative study.  However, the S143N and 
V255 mutations in all of the peptide triazole-treated cultures of the comparative study, as 
well as the presence of V255I and a similar pocket filling S375N mutation from the 
preliminary passaging, are indicative of a common mechanism for neutralizing the virus 
and inducing gp120 shedding.  It also demonstrates that evolving mutations to specifically 
overcome virolysis could be more of a burden on the virus.  Subsequently, the virus would 
develop escape mutations down a pathway that is more easily achieved instead, such as 
binding disruption.  Currently, there is roughly a 100-fold difference between the IC50 
values of neutralization and lysis caused by KR13, where neutralization is observed in the 
low nanomolar range and lysis is in the low micromolar.  This is the likely rationale behind 
the lack of virolysis specific escape in the comparative study.  As we increase binding 
potency and improve the lysis potency to decrease the gap in IC50 values with future 
generations of inhibitors, by optimizing the inhibitor scaffold to overcome known escape 
mutations, then mutations directly pertaining to the virolysis mechanism are more likely to 
become selected through virus evolution.   
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The only difference observed between the two classes was the presence of the R476K 
mutation in some of the KR13-treated cultures.  Mutations at position R476 have been 
observed previously by our laboratory to disrupt peptide triazole binding [58].  The alanine 
mutation investigated showed a low level of resistance, supporting our present data.  
Previous molecular dynamics simulation, modeling, and experimental data suggest that the 
N-terminus of the peptide may be projected towards and interact with this residue [49, 58, 59].  
A more conservative mutation like lysine displays similar disruption, which may suggest 
that the guanidyl group has the potential to slightly enhance linear peptide triazole binding 
by interacting with residues near the N-terminus of the peptide.  The cyclic nature of 
AAR029B does not have the potential for these same contacts due the N-terminus being 
engaged in the cyclic structure, which is an explanation as to why this mutation was absent 
in AAR029B-treated cultures.  Another potential explanation as to why the larger linear 
peptides develop the R476K mutation in the virus, whereas the cyclic peptide did not, is 
that the Env structure may be altered in a way that affects larger peptides 
disproportionately, such as decreasing the size of the binding cavity.  Interestingly, both 
inhibitors responded similarly to the individual R476K mutation in the pseudovirus 
background, in terms of providing an intermediate resistance phenotype.  The R476K still 
resulted in a larger fold-change from wild-type for KR13 than AAR029B, which would 
support its more important role in linear peptide triazole resistance.  Regardless, these 
mutations were lost in 2 of the 3 cultures at week 15 of the passaging study, which may 
suggest it is not a required mutation because crucial mutations should persist in passaging.  
Alternatively, the R476K mutation may require additional mutations to achieve this effect 
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that could not be directly determined with our experimental approach.  We did not explore 
individual viral clones, therefore, it is possible that these mutations occur on different 
viruses and the stronger virus was selected.  To determine which mutants are co-evolved 
or co-selected, we plan to investigate this further using deep sequencing and/or direct Env 
cloning in our future studies. 
 
The presence of the S143N mutation was an intriguing observation early in the analysis 
because it appeared to be located away from any Env structural features that we initially 
hypothesized as being important based on previous results [58, 60, 69].  However, this mutation 
was also observed in a previous HIV evolution study that derived viruses capable of 
restoring fitness to a gp41 mutation that induced gp120 shedding [82].  This mutation, along 
with other mutations that disrupt glycosylation in the V1 loop, significantly improved 
gp120-gp41 association [82].  This discovery ultimately led to their hypothesis that 
removing the glycosylation along the V1 loop would shift the importance of residues along 
the binding interface of the protein complex, thus allowing improved binding to their gp41 
mutant [82].  Since peptide triazoles induce gp120 shedding, we were particularly interested 
in this mutant.  Alone, this mutation only showed a marginal change in resistance to either 
inhibitor, which is consistent with earlier observations from the passaging experiments.  
From the preliminary study, a similar mutation to S143N was also generated in Culture 2 
(T138I), which also removes a glycosylation site within the V1 loop, highlighting the 
importance of this epitope.  To investigate how removal of V1 glycosylation affects peptide 
triazole-induced gp120 shedding, we are planning to test the effect of these mutations in 
our gp120 shedding experiments.  These mutations could provide valuable information 
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regarding how peptide triazoles induce shedding, but also vital clues regarding how 
shedding occurs universally and the impact this epitope has in relation to the overall protein 
complex. 
 
Additionally, there was a difference between how each inhibitor class responded to the 
S143N mutation.  AAR029B was less affected by the S143N mutation than KR13.  If the 
S143N mutation leads to a stronger gp120-gp41 interaction, then this may imply that the 
gp120 shedding is more critical for KR13 neutralization than AAR029B.  Both inhibitors 
have nearly identical potencies for shedding and CD4/17b blocking [47, 53].  However, the 
poses they adopt in the gp120 binding pockets may differ and hence be impacted 
differentially by the mutation.  Due to the constrained nature of the cyclic peptide, the 
binding within gp120 could be less flexible compared to the linear peptide.  Based on the 
fold-difference from wild-type Env, this restriction appears to be less affected by the 
mutation when compared with the linear inhibitor.  It will be important for future drug 
design to evaluate more broadly the impact of conformational restriction on virus resistance 
to cyclic peptide triazoles. 
 
Importantly, the observed S143N mutation in the virus culture persisted throughout the 
passaging experiment, suggesting that it was potentially important for resistance or that it 
did not incur a negative fitness cost for the virus.  Conversely, the V255 mutations were 
shown to drive the virus into a less infectious state, which is likely caused by disrupting 
CD4 binding of the host cell. Remarkably, we saw more than a doubling of infection, 
compared to the wild-type, when the V255T mutation was paired with the S143N mutation.   
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The similar co-evolution pattern of T138I/V255I observed in Culture 2 of the preliminary 
study suggests that this may be a mechanism to overcome the defect associated with a V255 
mutation.  We propose that these combinations may alter the viral spike to increase 
infection through a specific mechanism. These mechanisms may be by promoting CD4 
binding, increasing gp120-gp41 interaction, increasing spikes numbers, or evolving to gain 
CD4 independence.  To test for increased CD4 binding, we will investigate whether the 
double mutant can bind CD4 using surface plasmon resonance.  Increased gp120-gp41 
interactions and spike numbers will be determined by measuring gp120 quantity and 
retention on the virion.  Finally, we will investigate whether the virus evolved to gain CD4 
independence, by measuring infection on CD4-negative cells that still express co-receptor 
(HOS.X4 cells), since the loss of glycosylation at V1/V2 can enable entry into cells that 
express no CD4 or at minimal levels [83, 84]. 
 
Throughout both passaging experiments, it was quite evident that the potential loss of 
glycosylation was a common occurrence and may also be important for the specific HIV 
escape mechanism from peptide triazoles.  The heavy glycosylation present on gp120 
typically provides a shield to neutralizing antibodies, making it hard to develop broadly 
neutralizing antibodies [34, 85]. Conversely, the loss of glycosylation on HIV gp120 in 
association with resistance to entry inhibitors led to an increase in susceptibility to antibody 
neutralization [86-88].  The loss of glycosylation in the gp120 V1 loop observed through 
multiple mutations, S143N and T138I, in our study has been shown to aid the virus in 
escape from peptide triazoles.  If the glycosylation loss is indeed critical for improving 
infectivity or evading shedding, then the mutation would cause the virus to be more prone 
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to neutralization by the immune system. This strategy of driving virus resistance to one 
molecule and thereby creating a new vulnerability to an additional selection pressure, such 
as host antibodies, could be exploited clinically.  Since there is no selection pressure from 
antibodies in our experiment, it is hard to know exactly whether this mutation would be 
selected in vivo.  Nonetheless, this illustrates another potential therapeutic advantage that 
may develop through the continued advancement of peptide triazoles. 
 
It is also very interesting that additional mutations were observed outside the binding 
pocket in both the preliminary and comparative passaging experiments.  This discovery 
facilitates our understanding that peptide triazoles induce changes throughout the Env 
protein complex.  Among these mutations, we observed clustering of mutations along the 
gp120-gp41 interface and around the V3 loop that support our hypothesis of viral escape 
from the peptide triazole gp120 shedding and virolysis mechanisms, respectively (Figure 
19).  Mutations around the V3 loop occurred in the preliminary study, which only looked 
at the pressure asserted by KR13.  This resistance mechanism fits our hypothesized model 
that the V3 loop disulfide is the potential triggering event for the virolysis cascade 
mechanism proposed by Bailey et al. 2015 [60].  Mutational data and lysis competition with 
2G12, which binds adjacent to the V3 disulfide, have highlighted the importance of this 
epitope. The T297I mutation observed in our experiment is a known resistance mutation to 
2G12 [89].  This particular resistance is achieved through the loss of glycosylation within 
the 2G12 epitope, which has the potential to change the local environment and the structure 
of the loop.  Monitoring virolysis with this mutant through further mechanistic studies can 
help explain how peptide triazole thiols release p24.  Another mutation, N301K, disrupts a 
	 71	
glycosylation near this location and may induce similar affects as the T297I mutation.  
N301 has also been reported as a co-receptor binding site residue within the V3 loop [90], 
which may have altered binding with the mutation to lysine.  To a similar effect, the G321R 
mutation will likely affect the overall charge of the V3 loop and therefore have an effect 
on co-receptor binding. Collectively, these data support that the mechanism for peptide 
triazole virolysis is potentially initiated at the V3 loop disulfide.  
  
Additionally, shedding of gp120 from the envelope complex is a major hallmark for 
peptide triazoles. Therefore, we searched for mutations that would shed light on the gp120 
shedding mechanism.  Mutations along the gp120-gp41 interface were observed in both 
passaging studies, indicating a commonality between the two peptide functional 
mechanisms.  In our preliminary analysis, the V84A and A525T mutations on gp120 and 
gp41, respectively, developed and demonstrated that mutations can occur on either side of 
the gp120-gp41 interface.  The comparative escape study yielded the V87A mutation as a 
quasispecies in a few cultures, but it did not become a predominant mutation, which may 
be due to other mutations with stronger contributions to the observed resistance in culture.  
When brought into perspective with the V1 glycosylation loss mutations, an important 
evolutionary feature for the virus to overcome peptide triazole neutralization was to alter 
or strengthen the gp120 interaction with gp41 or to increase gp120-gp41 association.  
Ultimately. testing these mutations in a gp120 shedding assay will help discern their 
importance in peptide triazole-induced shedding.   
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Figure 19.  Clustering of mutations focuses near the V3 loop disulfide and the gp120-gp41 
interface.  Depiction of the escape mutations (red) that arose around the V3 loop disulfide 
(yellow) and the gp120-gp41 interface on a HIV-1 trimer (5FUU). 
 
 
 
We will seek to use outcomes of this work to inform future design of peptide triazoles.  
Virus escape mutations have been used in other systems to improve inhibitor design in the 
past [91-93].  Those studies have been performed in conjunction with a crystal structure.  In 
the absence of a crystal structure, mutational observations provide the most information in 
regards to the structural impact of particular residues involved with inhibitor binding.  
V255 mutations yielded the greatest increase in resistance among the mutations selected in 
this study.  Molecular docking analyses provided an explanation for this resistance by 
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showing that space filling mutations at this position could interfere with the insertion of 
the large ferrocene moiety into the hydrophobic pocket next to residue W112 of gp120, 
which is responsible for stabilizing the bridging sheet formation. Altering the functional 
groups at the azidoproline position could improve the binding of the inhibitor and also 
increase the resistance barrier.  For example, decreasing the size of the functional group 
may force a larger mutation to evolve to provide the same pocket filling effect.  A larger 
amino acid mutation will require more genomic mutations and most likely incur a larger 
fitness cost because of the highly conservative nature of this residue. 
 
Future escape studies with optimized inhibitors will display more pathways the virus can 
use for evading neutralization, shedding, and virolysis.  Utilizing these results for further 
improvement will enhance the clinical efficacy of these inhibitors by providing a structure-
based rational approach to inhibitor design and a methodology to test whether these 
improvements lead to a delay in the kinetics of viral escape. Ultimately, these studies will 
help create a better drug with less chances of developing drug resistance.  
 
Overall, the data derived from this thesis has elucidated that the main escape mechanism 
to current peptide triazoles is through binding disruption.  Despite the ability of KR13 to 
induce cell-free lysis, resistance to both classes occurs similarly suggesting that the 
difference between the neutralization and lysis IC50 values would need to be narrowed 
before we can identify specific lysis-preventing mutations.  The work herein will also help 
aid future drug design by demonstrating the importance of peptide conformation within the 
binding pockets, since cyclic peptide triazoles were less affected by mutations.  
	 74	
Improvements in peptide potency can also be implemented based on how the escape 
mutants interact with the peptide triazoles.  Pocket filling mutations such as V255I/T 
mutations arose in both passaging experiments, suggesting the sensitivity of peptide 
binding to side chain variations at this residue.  Future inhibitors can be designed to 
overcome this vulnerability, such as replacing the ferrocenyl with other moieties. 
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Chapter 3:  Future Directions 
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3.1.   Introduction 
 
This thesis has enabled the understanding of HIV-1 escape to different peptide triazole 
classes.  Previous work only provided a glance at which mutations were important for 
peptide triazole resistance by using alanine scanning mutagenesis and generating select 
mutations based on literature [47, 58].  Herein, we were able to determine a resistance 
pathway for HIV-1 to evade peptide triazole neutralization, which was visualized in two 
independent experiments.  The mutations discovered in this study have either been entirely 
new to our research or have enhanced our understanding of their importance to peptide 
triazole neutralization. 
 
While the work presented in this thesis has advanced our understanding of resistance to 
peptide triazoles, there are still many unanswered questions that warrant further 
investigation.  Understanding more about how these mutations arise, through deep 
sequencing analysis, and how they alter peptide triazole function, such as shedding and 
lysis will allow for better design of future inhibitors and provide more information about 
how to target vulnerabilities of the protein complex.  
 
3.2.  Next Generation Sequencing  
 
To deepen our knowledge regarding how the virus evolves to evade the selective pressure 
asserted by both classes of peptide triazoles, we will perform next-generation sequencing 
of the virus genome using Illumina technology.  The identical HIV-1 Env specific PCR 
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fragments used in the Sanger sequencing were generated biweekly for each KR13- and 
AAR029B-treated culture as well as for the untreated passaging control.  We will be 
performing this analysis with samples every two weeks to allow for an in depth analysis to 
track how HIV-1 evolved over time in response to peptide triazole inactivating pressure. 
 
By having samples throughout the entire passaging, we can determine a more precise 
moment when resistance arises.  We can also use this technique to determine which 
mutations co-evolve and their frequency.  Co-evolution is common between mutations 
because often a single mutation may not be enough to confer resistance or may come at a 
fitness disadvantage.  Previous deep sequencing runs in our lab had very deep coverage 
(~50,000 reads/base) which should allow for more power in analysis.   
 
If we are still not satisfied with the statistical power of this approach, we can perform 
cloning experiments to generate individual viral clones.  The entire Env gene will be 
amplified as a single PCR fragment and cloned into an expression vector.  Transformation 
of these plasmids into bacterial cells will allow for selection of individual clones.  These 
clones will be isolated and purified before sequencing to determine their genotype. 
 
3.3.  Determination of Cross-Resistance to Current HIV-1 Entry Inhibitors 
 
Resistance to an entire class of drugs is problematic in the clinic.  Understanding the cross-
resistance between other entry inhibitors is important during drug advancement to make 
sure the virus does not gain an advantage.  Cross-resistance between structurally diverse 
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entry inhibitors has been observed previously with the respiratory syncytial virus fusion 
(RSV F) protein [94].  The likelihood of a similar cross-resistance mechanism is high in 
HIV-1, since the RSV F protein is another example of a metastable fusion protein.  
Determining cross-resistance also provides information regarding the mechanism of the 
inhibitors analyzed and the protein of interest.  Ideally, resistance to one inhibitor would 
make the virus more sensitive to another class.  We will test the neutralization potency of 
different entry inhibitor classes.  Small-molecule CD4 mimetics [95], fusion inhibitors [73, 
78], co-receptor inhibitors [96, 97], and neutralizing antibodies [98, 99] will be utilized for this 
study.  They will be used in our infection inhibition assays against peptide triazole resistant 
virus, such as V255I/T or S143N pseudoviruses, and the difference between wild-type 
virus will be monitored.  From these data, we will be able to determine whether there is 
cross-resistance, but also apply this information to better understand how peptide triazoles 
neutralize HIV.  For example, similar escape mutants have been found to develop with 
both peptide triazoles and CD4 mimetics, and in both cases they disrupt inhibitor binding 
to gp120 [100].  A similarity in resistance through binding disruption implies that their 
binding epitopes may overlap.  Some potential cross-resistant mutations occur outside of 
the putative binding epitopes, which can be used to define specific vulnerabilities within 
the Env glycoprotein.  This can allow us to determine how these mutations alter the virus 
spike to evade both classes and also understand the pathways that the virus can use to 
escape neutralization. 
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3.4.  Determination of the Peptide Triazole-Induced gp120 Shedding Mechanism 
 
The gp120 shedding mechanism of peptide triazoles has, so far, been elusive.  Selected 
point mutations based on literature and looking at different structures have been the only 
method available.  Unfortunately, a structure of the entire Env complex has not been 
accessible until recently.  However, the viral escape analysis has yielded new mutations 
that directly developed based on peptide triazole selective pressure.  These mutations can 
be used to help elucidate the structural elements on the virus that respond to peptide triazole 
binding and cause release of gp120 from the trimer.  The loss of V1 glycosylation and the 
specific mutations along the gp120-gp41 interface are a great launching point for this 
investigation.  Monitoring phenotypic consequences, such as gp120 retention, and testing 
these mutations in gp120 shedding assay will provide the necessary data to investigate their 
role in shedding.  Additional phenotyping will need to be confirmed as well.  These include 
measuring spike numbers, infectivity levels, and the ability to negotiate typical Env 
transitions.   
 
Since there was a large difference in KR13 and AAR029B sensitivity towards mutations, 
particularly with the S143N mutation that might affect shedding, we will investigate how 
each of these peptides responds to mutations affecting shedding.  It is possible that linear 
peptide triazoles rely more on shedding than cyclic peptide triazoles.  For example, if 
shedding is induced more by the linear peptide, then it could mean that there is a 
requirement for peptide conformational change in gp120 following gp120 shedding 
triggering.  If this is true, then it would be a major discovery for the mechanism of both 
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peptide triazole classes.  All together, these data will help uncover the gp120 shedding 
mechanism caused by peptide triazoles and determine if there is a true difference between 
the peptide classes.  The data also can lead to identification of mechanisms within the Env 
trimer that are utilized by other shedding molecules, including CD4, CD4 mimetics, and 
MPER antibodies, in addition to peptide triazoles. 
 
3.5. Evaluation of the Mechanism of Mutant Virus Escape 
 
This thesis was able to show that the main mechanism of escape occurred through binding 
disruption.  However, even smaller mutations, such as S143N and R476K, resulted in 
differing shapes of the neutralization curves when compared to V255 mutations.  The 
difference in curvature, which relates to the Hill coefficient, suggests that there is an 
underlying difference in inhibition mechanisms by different mutants. Hill coefficients 
larger than 1 in an entry inhibition assay imply that more than one inhibitor is needed for 
blocking virus entry.  S143N and R476K had coefficients less than one, whereas the V255 
mutations had values approximately equal or greater than one.  The S143N and R476K 
mutations had similar curves to wild-type virus suggesting that the overall mechanism of 
neutralization to peptide triazoles did not change with these mutations and one peptide 
binding to a protomer can induce changes in the trimer that lead to neutralization.  
However, the V255I/T mutations had a much sharper curve, which implies that the 
mechanism for neutralization was altered by these mutations and may require additional 
peptide occupancy in the trimer to cope with the potential pocket-filling nature of these 
mutations.  In this case, the V255I/T mutations appear to either stabilize the trimer so that 
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the energy of a single peptide binding is insufficiently able to promote conformational 
triggering of the Env for neutralization or through a kinetic mechanism where the lifetime 
of a single peptide-bound state is too short-lived to induce the proper conformational 
change.  In the latter instance, additional binding of peptide triazoles could enhance the 
probability of triggering, which would result in virus entry inhibition.  Therefore, we 
hypothesize that engagement of one protomer causes enough perturbation for typical 
neutralization of wild-type, whereas the V255I/T need simultaneous occupancy of 
additional protomers on the spike to trigger enough destabilization of the trimer to 
neutralize the virus.  This hypothesis helps explain why there is such a dramatic drop in 
potency as you dilute peptide concentrations in the inhibition assays.  We plan to 
investigate this potential mechanism by performing a kinetic analysis of entry inhibition 
with wild-type and mutant viruses.  Inhibitor and virus will be diluted and mixed according 
to our standard infection inhibition assay, but we will also vary the incubation times before 
adding to cells.  The results should produce a delay in V255 mutant neutralization kinetics, 
when compared to wild-type, if these mutations require more time for multiple peptides to 
bind and actuate Env triggering. To further investigate this hypothesis, we can perform a 
hybrid Env experiment previously used in our laboratory [69], which will allow us to 
confirm whether multiple binding events are necessary for neutralization.  This technique 
allows for dilution of different Env, both wild-type and mutant, to form chimeric Env 
spikes with varying amounts of the mutant Env.  The composition of each spike can be 
calculated theoretically based on DNA concentration and random incorporation.  This will 
establish a ratio of the number of spikes required for neutralization and demonstrate 
whether more binding events are necessary. Collectively, these experiments will help show 
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whether the difference in neutralization kinetics forces the peptide to bind to more proteins 
in the spike in order to achieve neutralization of the mutant Env or if there is another 
mechanism that will need to be elucidated. 
 
3.6. Optimizing the Peptide Triazole Structure to Counteract Resistance 
 
Now that we have an understanding of how resistance can arise, we can utilize this 
information to improve the overall design of our peptide triazole inhibitors.  From this 
study, we know that the V255 mutations were the most critical mutation involved with 
resistance.  Flexible docking showed that the large ferrocenyl group may be sterically 
blocked by the isoleucine or threonine mutations.  Changing the functional group at the 
position could potentially alleviate this steric clash and allow binding to the resistant 
gp120.  Our laboratory has already synthesized derivatives at this position, such as 
AAR029I, which has a methyl benzene group in place of the ferrocene.  This inhibitor 
exhibits strong nanomolar binding and has a smaller moiety attached to the azidoproline.  
It is conceivable that this molecule and others that are similar may be able to counteract 
the resistance associated with the V255I/T mutation.  Even if they are slightly less potent, 
they may have a higher resistance barrier or could be more active against the mutated Env.  
This would allow the new inhibitor to be used in conjunction with the previous inhibitor to 
collectively make the virus susceptible to neutralization.  Also, since we now have more 
proof that the V3 loop is a potential vulnerability to triggering lysis, we can design potent 
new macrocyclic peptide triazole thiols.  Docking data can be used to find the best 
configuration and linker to more readily achieve lytic activity.  Therefore, the results from 
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the viral escape analysis will provide new approaches for achieving better neutralization of 
HIV-1. 
 
3.7.  Future Passaging Studies to Monitor Resistance to New Inhibitors 
 
Our laboratory is currently synthesizing new inhibitors based on our current scaffold that 
have improved potency and display more drug-like properties.  Information obtained from 
this thesis will also be implemented in drug design, as mentioned above, which will 
generate new classes of peptides that will need to be screened. As these new designs 
advance, we can utilize virus passaging to observe which mutations arise in culture.  These 
new mutations will provide insight regarding inhibitor function that can be used again in 
inhibitor design.  Utilizing the data from these analyses, we can improve binding and 
continue to increase the resistance threshold and ultimately obtain a better clinical outcome. 
 
We also have additional projects with a bifunctional chimera, composed of a peptide 
triazole and a co-receptor inhibitor that is tethered by a linker, and a new class of molecule 
that hypothetically binds near the gp120-gp41 interface that would benefit from escape 
analysis.  The mechanism of these inhibitors is still unknown and virus escape can help 
with identifying viral protein elements that can uncover a structural mechanism.  Also, 
viral escape will allow us to measure whether there is an advantage to advancing these 
inhibitors. For example, the bifunctional chimera has a large contribution of neutralization 
from the very potent co-receptor inhibitor, but resistance arises in culture and within 
patients to allow the virus to bind to the inhibitor-bound co-receptor.  We believe that the 
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large peptide moiety tethered to the co-receptor inhibitor will decrease this potential and 
raise the resistance barrier.  It will also allow for potentially understanding complex 
resistance pathways that the virus can utilize since there are multiple inhibitors present 
within the culture. 
 
3.8.  Overall Impact 
 
This body of work has determined a pathway that HIV-1 can utilize to escape neutralization 
to peptide triazoles.  Escape occurs through mutations that lead to peptide triazole binding 
disruption and also mutations throughout the Env glycoprotein, which showcases the 
plasticity of the protein complex.  The plasticity allows HIV-1 Env to survive perturbations 
triggered by inactivating molecules that attempt to hijack the metastability of the 
glycoprotein.  Other viruses, such as Ebola and Influenza, share a similar type-1 entry 
machinery and proceed down a similar energy landscape as HIV-1, due to a high energy 
native state [85, 101].  Understanding how HIV-1 can escape inactivation by triggering 
molecules like peptide triazoles through altering the entry machinery may help to 
determine how metastable viruses generally can evade inactivation and uncover common 
pathways that can be exploited with future inhibitors.  One of the inactivation pathways of 
peptide triazoles that exploits the metastability is the induction of surface protein, gp120, 
shedding.  Little is known about how shedding occurs other than it is a destabilization of 
the association between gp120 and gp41.  However, this thesis has provided new resistance 
mutants that could lead the way to determining how shedding is induced.  The peptide 
triazole-induced shedding may be the same method that other molecules known to induce 
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shedding, such as CD4 mimetics and MPER antibodies [102, 103], utilize to inactivate the 
virus, which will allow us to determine and exploit a major vulnerability of the metastable 
Env complex. 
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